详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy

13| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China. [2]Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [3]Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. [4]Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. [5]Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China. [6]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [7]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China. [8]Department of Hematology, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, China. [9]National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. [10]Guangzhou Healthquest Pharma Company Ltd., Guangzhou, China. [11]Peking University People's Hospital, Qingdao, China.

出处：

DOI：

ISSN：

关键词： chronic myeloid leukemia health‐related quality of life (HRQoL) olverembatinib Self‐Rating Anxiety Scale (SAS) Self‐Rating Depression Scale (SDS)

摘要：

The objective of this study was to assess patient-reported outcomes (PROs), including health-related quality of life (HRQoL) and anxiety and depression symptoms, and to identify associated variables in patients with tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML) in chronic-phase (CP) or accelerated-phase (AP) who were receiving olverembatinib.Patients in multicenter studies were invited to complete the European Organization for Research and Treatment of Cancer Quality-of-Life Core 30 Questionnaire, the Self-Rating Anxiety Scale, and the Self-Rating Depression Scale at baseline and regularly during olverembatinib therapy. The time trends in PROs were estimated with a linear model using a generalized estimating equation based on an independent working correlation matrix. A generalized estimating equation model was used to assess the variables associated with PROs.In total, 146 patients with CML-CP or CML-AP were included in this study. Scores on seven items from the European Organization for Research and Treatment of Cancer Quality-of-Life Core 30 Questionnaire, including global health, physical functioning, emotional functioning, fatigue, dyspnea, diarrhea, and financial difficulties, improved significantly over time during olverembatinib therapy. In multivariate analysis, age younger than 40 years was significantly associated with greater improvement in social functioning (p = .033), and CML-CP (vs. CML-AP) was associated with greater improvements in dyspnea (p = .031) and diarrhea (p = .031) over time. Scores on the Self-Rating Anxiety Scale and the Self-Rating Depression Scale decreased significantly over time during olverembatinib treatment (p < .001).The authors concluded that HRQoL significantly improved over time during olverembatinib therapy in heavily treated patients with TKI-resistant CML, especially among those who were younger and those who had CML-CP. Anxiety symptoms also significantly decreased over time.© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 2 区

医学

小类 | 2 区肿瘤学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 ONCOLOGY

影响因子： 6.1 最新[2023版] 6.7 最新五年平均 6.1 出版当年[2023版] 0 出版当年五年平均 6.1 出版前一年[2023版]

第一作者：

第一作者机构： [1]Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China.

共同第一作者：

通讯作者：

通讯机构： [1]Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China. [11]Peking University People's Hospital, Qingdao, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy

文献详情

相关文献